Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

Faster, Cleaner, Better.

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Vyne Therapeutics Inc (VYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update GlobeNewswire - Thu Nov 6, 7:00AM CST

Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of internal pipeline opportunities and broader strategic...

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update GlobeNewswire - Thu Aug 14, 7:00AM CDT

BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated...

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo GlobeNewswire - Wed Jul 30, 7:00AM CDT

Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from...

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 GlobeNewswire - Wed Jul 2, 6:45AM CDT

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update GlobeNewswire - Thu May 8, 7:00AM CDT

VYNE Therapeutics Provides Update on VYN202 Program GlobeNewswire - Fri Apr 25, 7:00AM CDT

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference GlobeNewswire - Thu Mar 20, 7:00AM CDT

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update GlobeNewswire - Thu Mar 6, 7:00AM CST

VYNE Therapeutics to Participate in March Investor Conferences GlobeNewswire - Thu Feb 20, 7:00AM CST

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis GlobeNewswire - Wed Feb 19, 7:00AM CST